Selection of 5 Posters
M Harris, et al. POSTER
The authors of the study conclude that "Early data indicates that the use of EUS-guided implantation of P-32 is highly feasible, well tolerated and has an acceptable safety profile in combination with standard first-line chemotherapy for LAPC. Preliminary data shows evidence of tumour regression and local disease control. These results, however, warrant further evaluation. The clinical trial is ongoing and additional safety and efficacy data will be presented. ClinicalTrials.gov Identifier: NCT03003078. Acknowledgement: Nab-paclitaxel was supported by Specialised Therapeutics Australia Pty Ltd."
Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.140, https://doi.org/10.1093/annonc/mdy151.140
Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.141, https://doi.org/10.1093/annonc/mdy151.141
Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.142, https://doi.org/10.1093/annonc/mdy151.142
Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.146, https://doi.org/10.1093/annonc/mdy151.146
Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.160, https://doi.org/10.1093/annonc/mdy151.160